背景:AICyte先前已证明在宫颈细胞学筛查中具有潜在的作用,可通过使用50%的负临界值来减少工作量。本研究的目的是评估这一假设。
方法:作者使用RuiqianWSI-2400(注册商标AICyte)评估了2018年至2023年从中国四个不同医院系统收集的163,848例原始宫颈细胞学病例。案件细分包括来自深圳的46,060起,郑州67,472,石家庄25667人,和24,649来自济南。这些收集的病例使用AICyte系统进行了评估,并将收集的数据与原始解释结果进行统计比较。
结果:在98.80%被指定为不需要进一步审查的人工智能案例中,相应的原始诊断也被确定为阴性。对于任何被指定为非典型鳞状细胞的病例,不能排除高度鳞状上皮内病变或更高,敏感性和阴性预测值分别为90.77%和98.80%,分别。在指定为低度鳞状上皮内病变或更高的病例中,敏感性和阴性预测值更高,分别为98.92%和99.94%,分别。在AICyte设计的不需要进一步检查的49例低级别鳞状上皮内病变或更高级别病变中,细胞组织学相关性显示宫颈上皮内瘤变1例8例,阴性18例;其余病例无组织学随访。在实践中,如果将方案实施为在负临界值内合格的病例标记为不需要进一步审查,则以50%负临界值使用的AICyte可以减少预期的工作量。从而最终确定病例为上皮内病变和恶性肿瘤阴性。
结论:对于没有细胞技术人员的病理实践,或者对工作流程进行优化,人工智能系统AICyte单独使用50%的负截止值作为独立的筛选工具,这是宫颈癌筛查的一种潜在辅助方法。
BACKGROUND: AICyte has previously demonstrated a potential role in cervical cytology screening for reducing the workload by using a 50% negative cutoff value. The aim of the current study is to evaluate this hypothesis.
METHODS: The authors used the Ruiqian WSI-2400 (with the registered trademark AICyte) to evaluate a collection of 163,848 original cervical cytology cases from 2018 to 2023 that were collected from four different hospital systems in China. A breakdown of cases included 46,060 from Shenzhen, 67,472 from Zhengzhou, 25,667 from Shijiazhuang, and 24,649 from Jinan. These collected cases were evaluated using the AICyte system, and the data collected were statistically compared with the original interpretative results.
RESULTS: In 98.80% of all artificial intelligence cases that were designated as not needing further review, the corresponding original diagnosis was also determined to be negative. For any cases that were designated atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion or higher, the sensitivity and negative predictive value were 90.77% and 98.80%, respectively. The sensitivity and negative predictive value were greater in cases designated as low-grade squamous intraepithelial lesion or higher at 98.92% and 99.94%, respectively. Of the 49 low-grade squamous intraepithelial lesion or higher that were designed by AICyte as not needing further review, the cytohistologic correlation revealed eight cases of cervical intraepithelial neoplasia 1 and 18 negative cases; and the remaining cases were without histologic follow-up. In practice, AICyte used at a 50% negative cutoff value could reduce the anticipated workload if a protocol were implemented to label cases that qualified within the negative cutoff value as not needing further review, thereby finalizing the case as negative for intraepithelial lesions and malignancy.
CONCLUSIONS: For pathologic practices that do not have cytotechnologists or in which the workflow is sought to be optimized, the artificial intelligence system AICyte alone to be an independent screening tool by using a 50% negative cutoff value, which is a potential assistive method for cervical cancer screening.